Dossier assessment

Pixantrone - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

Status
Status: Commission completed
Project no.
A12-17
Last updated

Report documents

  1. Extract of dossier assessment

    Pixantrone - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

    published on
    Document type
    PDF document, 96 kB, EN, not accessible
  2. Dossier assessment

    Pixantrone - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

    published on
    Document type
    PDF document, 294 kB, DE, not accessible

Press releases

Pixantrone: no proof of added benefit

Drug manufacturer did not present any suitable data: patients in the comparator group were not treated according to approval status

Additional information

Federal Joint Committee (G-BA)

2013-05-16 A G-BA decision was published.

G-BA documents on this decision (German only)

Project details

Project no.
A12-17
Commission
Commission awarded on 30.11.2012 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form